Mylan goes commercial in India as it launches large antiretroviral portfolio
This article was originally published in Scrip
Executive Summary
Mylan, the world's third-largest generics and specialty pharmaceutical firm, has kicked off commercial operations in India, introducing more than a dozen antiretrovirals (ARVs) for HIV/AIDS onto the market.